Timelines, pharmaceutical

As things stand today, there are no shortcuts in drug development, regarding neither the overall development time—typically 12-15 years—nor the early identification of dropouts. The pharmaceutical industry will continue to have to contend with failure rates and timelines to bring products to market exceeding industry standards by far. 

Many challenges remain, however, in realizing the vision of individualized drug selection and optimization, and it should be acknowledged that the timelines for gains in clinical knowledge and real-life applicability will always lag behind the pace of basic scientific discovery. Success in this endeavor will continue to require a close collaboration between academic, regulatory, and pharmaceutical partners. 

New Excipient Development Timeline Linked to First Pharmaceutical Product Development Timeline... 

The path which must be followed in the development of a material from lab bench to consumer is long, torturous and expensive. As stated before it takes about twelve years and over 200 million to bring an entity to the point of being marketed. Part of that timeline is understandable considering the laws governing safety and efficacy. Outlined in Figure 1 are the major steps on the way to a pharmaceutical product. 

Another way to control costs and reap higher profits, besides improving the statistics for a novel pharmaceutical hit by mergers and consolidations, lies in accelerating research and development through the six phases delineated in Table 13.2. Figure 13.4 illustrates the consequences of a faster development pace by comparing the traditional timeline with the novel, accelerated pace. 

Accelerated drug development schemes have shifted the need for analytical instrumentation to include criteria for high throughput (quantitative process approaches) and the capability to contribute to an application that produces information for accelerated decision making (qualitative process approaches). The value of sensitivity, selectivity, and detail are still significant however, new parameters dealing with efficiency, productivity, and information content have become the new watermarks for analytical instrumentation in the pharmaceutical industry. These factors have been affected by shorter timelines and the pharmaceutically relevant information required for decision making. 

Excipient and vendor selections can greatly influence the new drag development timeline, product performance, and acceptance of final products. Compendial excipients have composition consistent with monographs published in compendia such as USP-NF these are the better-characterized excipients. These excipients most likely possess desirable qualities and are preferred excipients for pharmaceutical formulations. Non-compendial excipients can also be used for drug products if they are supported by Type IV dmg master files (DMFs) in regulatory dossiers. Overall, a good excipient supplier should 29... 

Timeline initiation report Estimated cost Regulatory guidelines and compliance 2 to 4 weeks following authorization 4 to 6 weeks after termination 25,000 to 45,000 ICFI S7A safety pharmacology studies for human pharmaceuticals and FDA GLP... 

If a pharmaceutical company manufactures a multidose formulation, the timeline for the development of this dose is significantly greater than for a unit dose formulation. A multidose will require the incorporation of an antimicrobial agent (preservative) in the protein formulation. 

So far, no definitive decision mechanisms covering the choice of salt formers have been developed, so the final evaluation and selection process remains essentially empirical to a large extent. In addition to the reasons mentioned earlier that in the major pharmaceutical companies the search for crystalline salts occurs very early along the development timeline, there is further reason. Preclinical investigations are necessarily initiated at a time when the candidate drug substance is usually impure (often around 95% pure) and material is at a premium. Here the formation... 

This is often times very important for pharmaceutical production processes where interactions among factors are common. Ultimately, DOE allows the experimenter to determine which process factors are to be included in subsequent validation studies. By eliminating the insignificant factors from the validation work, a great deal of time and money can often be saved. In addition, by using DOE to streamline the development work and efficiently characterize the process, the timeline for product development and a successful commercial launch can be shortened significantly. 

Timelines for product development are continually being shortened in an effort to get a compound on the market as quickly as possible. Current and future trends and industry paradigm shifts are changing the face of clinical trials so that the pharmaceutical industry can look forward to global approval of new and old pharmaceutical products. 

---